Lisata Therapeutics, Inc.
LSTAHealthcare|Biotechnology|US
$1.03
+0.04 (+3.88%)
DCF Value
$1.91
Tangible Book / Share
$0.88
Cash / Share
$1.15
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01508910 Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina | Chronic Myocardial Ischemia, Refractory Angina Pectoris | P3 | Completed | 291 | RCT, Double-blind | Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells |
| NCT01875653 Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | Stage IV Melanoma, Stage III Melanoma | P3 | Terminated | 4 | RCT, Double-blind | Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC) |
| NCT03508609 Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease | Coronary Microvascular Dysfunction | P2 | Completed | 20 | Open-label | CLBS16 |
| NCT04614467 A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction | Coronary Microvascular Dysfunction, Coronary Microvascular Disease | P2 | Terminated | 34 | RCT, Double-blind | CLBS16, Placebo |
| NCT02501018 Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) | Critical Limb Ischemia, Buerger Disease | P2 | Completed | 33 | RCT, Open-label | CLBS12, SOC |
| NCT02691247 Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study) | Diabetes Mellitus | P2 | Completed | 113 | RCT, Double-blind | CLBS03 Low Dose, CLBS03 High Dose, Placebo |
| NCT01495364 NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction | ST Segment Elevation Myocardial Infarction | P2 | Completed | 195 | RCT, Double-blind | NBS10 |
| NCT06592664 Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC | Pancreas Cancer, Pancreatic Carcinoma | P1P2 | Withdrawn | — | RCT, Double-blind | certepetide, nab-paclitaxel, gemcitabine, placebo matching certepetide, certepetide, placebo matching certepetide, placebo matching certepetide |
| NCT05712356 A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | Cholangiocarcinoma, Gallbladder Cancer | P2 | Completed | 66 | RCT, Double-blind | certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo |
| NCT00814593 Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery | Brain and Central Nervous System Tumors | P2 | Withdrawn | — | RCT, Open-label | lymphokine-activated killer cells, polifeprosan 20 with carmustine implant |
| NCT00300053 ACT34-CMI -- Adult Autologous CD34+ Cells | Myocardial Ischemia | P2 | Completed | 321 | RCT, Double-blind | CLBS14 (low-dose), CLBS14 (high-dose), placebo injection |
| NCT00012064 Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma | Melanoma (Skin) | P1P2 | Completed | 56 | Open-label | therapeutic autologous dendritic cells |
| NCT03517176 CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | P1 | Completed | 30 | Open-label | CEND-1, Nab-paclitaxel, Gemcitabine |
| NCT04522817 CLBS119 for Repair of COVID-19 Induced Pulmonary Damage | Covid-19 | P1 | Withdrawn | — | Open-label | CLBS119 |
| NCT00014131 Vaccine Therapy in Treating Patients With Kidney Cancer | Kidney Cancer | P1 | Terminated | 9 | Open-label | Biological/Vaccine: therapeutic autologous dendritic cells. |
| NCT04990427 CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Diseases | P1 | Completed | 6 | Open-label | CLBS201 |
| NCT00545610 ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study) | Myocardial Ischemia | Completed | 150 | — | — |